Wuling San regulates AVPR2-cAMP-PKA-CREB pathway to delay cellular senescence and ameliorate acute kidney injury.

Hong Liu, Manxue Mei, Shuyin Lin, Jiahui Luo, Sirong Huang, Jiuyao Zhou

Department of Pharmacology, School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, 510000, China.Department of Pharmacology, School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, 510000, China. · pubmed

Paper

Abstract

Cellular senescence in renal resident cells plays a pivotal role in the progression of acute kidney injury (AKI), necessitating the expansion of effective drug targets. Traditional Chinese medicine (TCM) formulations, characterized by their multi-target effects, offer a promising perspective for advancing research on AKI. Wuling San (WLS), a well-established compound used in treating urological disorders, has yet to elucidate its potential pharmacological targets and mechanisms in ameliorating AKI and delaying cellular senescence.

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

Wuling San regulates the AVPR2-cAMP-PKA-CREB pathway to delay cellular senescence and ameliorate acute kidney injury. The paper is relevant as it explores a potential mechanism to delay cellular senescence, which is a key factor in the aging process.

Author of this paper? Send a correction.